S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)
NASDAQ:BBIO

BridgeBio Pharma (BBIO) Stock Price, News & Analysis

$34.63
+0.63 (+1.85%)
(As of 09:46 AM ET)
Today's Range
$33.66
$34.68
50-Day Range
$32.96
$43.89
52-Week Range
$10.57
$44.32
Volume
58,304 shs
Average Volume
1.75 million shs
Market Capitalization
$6.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.29

BridgeBio Pharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
24.4% Upside
$42.29 Price Target
Short Interest
Healthy
11.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.31
Upright™ Environmental Score
News Sentiment
0.15mentions of BridgeBio Pharma in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$4.40 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.80) to ($3.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.45 out of 5 stars

Medical Sector

109th out of 935 stocks

Pharmaceutical Preparations Industry

39th out of 429 stocks


BBIO stock logo

About BridgeBio Pharma Stock (NASDAQ:BBIO)

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Stock Price History

BBIO Stock News Headlines

BBIO Mar 2024 37.000 call
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
BridgeBio Pharma (NASDAQ:BBIO) PT Raised to $46.00
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
3BBIO : Recap: BridgeBio Pharma Q4 Earnings
BBIO Mar 2024 38.000 call
BBIO Feb 2024 36.000 put
BridgeBio Pharma (NASDAQ:BBIO) Trading Down 4.8%
BBIO Feb 2024 39.000 call
BBIO Feb 2024 39.000 put
3 Groundbreaking Biotech Stocks to Invest in Now
BridgeBio Announces FDA Acceptance Of NDA For Acoramidis
See More Headlines
Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
2/25/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
392
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$42.29
High Stock Price Target
$60.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+24.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-481,180,000.00
Net Margins
-6,913.92%
Pretax Margin
-6,613.21%

Debt

Sales & Book Value

Annual Sales
$9.30 million
Book Value
($8.32) per share

Miscellaneous

Free Float
124,352,000
Market Cap
$5.91 billion
Optionable
Optionable
Beta
1.07
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Neil Kumar Ph.D. (Age 45)
    Co-Founder, President, CEO & Director
    Comp: $2.1M
  • Dr. Charles J. Homcy M.D. (Age 76)
    Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
    Comp: $208k
  • Dr. Brian C. Stephenson C.F.A. (Age 43)
    Ph.D., CFO & Secretary
    Comp: $1.15M
  • Dr. Richard H. Scheller Ph.D. (Age 71)
    Chairman of Research & Development
    Comp: $202.4k
  • Dr. Frank P. McCormick Ph.D. (Age 74)
    Co-Founder, Chairman of Oncology & Director
  • Dr. Uma Sinha Ph.D. (Age 67)
    Chief Scientific Officer
    Comp: $1.31M
  • Grace Rauh
    Vice President of Communications
  • Mr. Eli M. Wallace Ph.D. (Age 57)
    Chief Scientific Officer of Oncology
  • Dr. Thomas Trimarchi Ph.D.
    Chief Product Officer
  • Dr. Eric Michael David J.D. (Age 52)
    M.D., Ph.D., Chief Executive Officer of Gene Therapy














BBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BBIO shares.
View BBIO analyst ratings
or view top-rated stocks.

What is BridgeBio Pharma's stock price target for 2024?

12 equities research analysts have issued 12 month price targets for BridgeBio Pharma's stock. Their BBIO share price targets range from $18.00 to $60.00. On average, they predict the company's share price to reach $42.29 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for BBIO
or view top-rated stocks among Wall Street analysts.

How have BBIO shares performed in 2024?

BridgeBio Pharma's stock was trading at $40.37 on January 1st, 2024. Since then, BBIO shares have decreased by 15.8% and is now trading at $34.00.
View the best growth stocks for 2024 here
.

When is BridgeBio Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BBIO earnings forecast
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.09. The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $4.78 million. The business's revenue for the quarter was down 8.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.92) EPS.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.36%), Hhlr Advisors LTD. (0.80%), Norges Bank (0.67%), Northern Trust Corp (0.66%), Charles Schwab Investment Management Inc. (0.65%) and Voloridge Investment Management LLC (0.64%). Insiders that own company stock include Brian C Stephenson, Douglas A Dachille, Frank Mccormick, Global Investors Lp Viking, Hannah Valantine, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends
.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BBIO) was last updated on 2/26/2024 by MarketBeat.com Staff